A Phase 1 interventional study of mRNA-1345 and mRNA-1365 in Respiratory Syncytial Virus and Human Metapneumovirus, sponsored by ModernaTX, Inc.. Active, not recruiting at 17 sites in 3 countries. Open to participants aged 5 Months to 24 Months. Per ClinicalTrials.gov, last updated 2026-06-26.
Sponsored by ModernaTX, Inc. (part of Moderna, Inc.) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to assess the safety and immunogenicity of mRNA-1365, an mRNA vaccine targeting respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) and mRNA-1345, an mRNA vaccine targeting RSV, in participants aged 5 months to \<24 months.
ModernaTX, Inc. is the lead sponsor of 119 studies on the registry; 18 are open to participants now.
Of its 64 completed or terminated interventional studies of FDA-regulated products, 35 (55%) have results posted.
Counted across the registry records on this site, refreshed daily.
Inclusion Criteria:
Exclusion Criteria:
Note: Other protocol-defined inclusion/exclusion criteria apply.
Inclusion Criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive mRNA-1345 vaccine by intramuscular (IM) injection on Days 1, 57 and 113.
Biological: mRNA-1345
Participants will receive mRNA-1365 vaccine by IM injection on Days 1, 57 and 113.
Biological: mRNA-1365
Participants will receive mRNA-1345/ mRNA-1365 vaccine matching placebo by IM injection on Days 1, 57 and 113. In countries where applicable, participants may receive Nimenrix instead of placebo on Day 113.
Biological: Placebo · Drug: Nimenrix
Participants will receive mRNA-1345 by IM injection on Days 1, 57 and 113.
Biological: mRNA-1345
Participants will receive mRNA-1365 by IM injection on Days 1, 57 and 113.
Biological: mRNA-1365
Participants will receive mRNA-1345 by IM injection on Days 1, 57 and 113.
Biological: mRNA-1345
Participants will receive mRNA-1365 by IM injection on Days 1, 57 and 113.
Biological: mRNA-1365
Participants will receive mRNA-1345/ mRNA-1365 vaccine matching placebo by IM injection on Days 1, 57 and 113. In countries where applicable, participants may receive Nimenrix instead of placebo on Day 113.
Biological: Placebo · Drug: Nimenrix
Participants will have the option to re-enrol in the Part B extension period.
Participants will have the option to re-enrol in the Part B extension period.
Participants will have the option to re-enrol in the Part B extension period.
Participants will have the option to re-enrol in the Part B extension period.
Participants will have the option to re-enrol in the Part B extension period.
Participants who have been previously exposed to nirsevimab will receive mRNA 1345 by IM injection on Days 1, 57, and 113.
Biological: mRNA-1345
Participants who have not been previously exposed to nirsevimab will receive mRNA 1345 by IM injection on Days 1, 57, and 113.
Biological: mRNA-1345
Sterile liquid for injection
Sterile liquid for injection
0.9% sodium chloride (normal saline) solution for injection
Solution for injection
Main Study: Number of Participants with Solicited Local and Systemic Adverse Reactions (ARs)
Time frame: Up to Day 120 (7 days after each injection)
Main Study: Number of Participants with Unsolicited Adverse Events (AEs)
Time frame: Up to Day 141 (28 days after each injection)
Main Study: Number of Participants with Medically-Attended Adverse Events (MAAEs)
Time frame: Day 1 through Day 730
Main Study: Number of Participants with Adverse Event of Special Interests (AESIs), Serious Adverse Events (SAEs) and Adverse Events Leading to Discontinuation
Time frame: Day 1 through Day 730
Part B Extension: Number of Participants with MAAEs, AESIs and SAEs
Time frame: Day 1 of the Extension to end of study (EoS) (up to 3 years)
Part B Extension: Number of Participants with Lower Respiratory Tract Illness (LRTI), Severe LRTI, Very Severe LRTI, and Hospitalizations Associated with RSV or hMPV
Time frame: Day 1 of the Extension to EoS (up to 3 years)
Main Study: Number of Participants with Respiratory tract Illness (RTI), LRTI, Severe LRTI, Very Severe LRTI, and Hospitalizations Associated with RSV or hMPV
Time frame: Day 1 through Day 730
Main Study (Parts A and B): Geometric Mean Titer (GMT) of Serum RSV and hMPV Neutralizing Antibodies
Time frame: Baseline up to Month 12
Main Study (Part C): GMT of Serum RSV Neutralizing Antibodies
Time frame: Baseline up to Month 12
Main Study (Parts A and B): Geometric Mean Concentration (GMC) of Serum RSV F- and hMPV F-Binding Antibodies
Time frame: Baseline up to Month 12
Main Study (Part C): GMC of Serum RSV F-Binding Antibodies
Time frame: Baseline up to Month 12
Main Study: Geometric Mean Fold-Rise (GMFR) of Postbaseline/baseline Neutralizing Antibody Titers and Binding Antibody
Time frame: Month 12
Main Study: Number of Participants with Vaccine-specific T-cell Responses Measured by Flow Cytometry
Time frame: Baseline up to Month 12
Part B Extension: Geometric Mean Titer (GMT) of Serum RSV and hMPV Neutralizing Antibodies
Time frame: Day 1 of the Extension up to EoS (up to 3 years)
Part B Extension: Geometric Mean Concentration (GMC) of Serum RSV F- and hMPV F-Binding Antibodies
Time frame: Day 1 of the Extension up to EoS (up to 3 years)
Part B Extension: Geometric Mean Fold-Rise (GMFR) of Postbaseline/baseline Neutralizing Antibody Titers and Binding Antibody
Time frame: Day 1 of the Extension up to EoS (up to 3 years)
Part B Extension: Number of Participants with Vaccine-specific T-cell Responses Measured by Flow Cytometry
Time frame: Day 1 of the Extension up to EoS (up to 3 years)
Started Feb 2023 (actual). Primary completion is estimated for Aug 2029, 78 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: mRNA-1345 respiratory syncytial virus vaccine